Fred Saad, ESMO 2022: Highlights in prostate cancer – Phase 3 trials in the STAMPEDE platform protocol

Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss clinical trial highlights in prostate cancer presented at EMSO 2022. He highlights the results from one of the phase 3 STAMPEDE trials, investigating combination abiraterone and enzalutamide or abiraterone and prednisolone, for metastatic hormone sensitive prostate cancer (mHSPC), and what these results might mean for future clinical practice, and the use of androgen deprivation therapy as standard of care.

Questions:

1. What are the hot topics and clinical trial highlights in prostate cancer from ESMO 2022? (0:11)

Disclosures: Fred Saad is a consultant for AstraZeneca; receives grant/research support from AstraZeneca; is on the advisory board for AstraZeneca; and receives honoraria/honorarium from AstraZeneca.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Filmed in coverage of ESMO 2022

Access more prostate and genitourinary cancer content here